JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

  • 0Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China.
World Journal of Gastrointestinal Oncology +

|

April 5, 2024

|

April 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Early detection of pancreatic cancer (PDAC) is crucial for improving survival rates. A novel serum N-glycan biomarker signature shows promise for identifying early-stage PDAC, enhancing diagnostic capabilities.

Area Of Science

  • Biochemistry
  • Oncology
  • Biomarker Discovery

Background

  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with survival rates below 10% due to late diagnosis.
  • Early detection of pancreatic cancer (PC) significantly improves patient survival outcomes.

Purpose Of The Study

  • To identify serum biomarker signatures for early-stage PDAC using N-glycan analysis.
  • To develop a diagnostic model for early-stage pancreatic cancer detection.

Main Methods

  • Utilized a case-cohort study design with a large patient cohort including early-stage PDAC (I and II) and controls.
  • Employed multiparametric analysis to identify specific N-glycan signatures.
  • Developed an N-glycan signature-based diagnostic model termed the "Glyco-model".

Main Results

  • A biomarker signature effectively discriminated PC patients from controls (AUC 0.86).
  • Combining the signature with cancer antigen 19-9 improved discrimination (AUC 0.919).
  • The Glyco-model showed high diagnostic performance across all PC stages, with 89.66% sensitivity for stage I PDAC.

Conclusions

  • The developed serum biomarker signature shows potential as a viable method for early-stage PDAC detection.
  • Prospective validation is recommended to confirm the clinical utility of this N-glycan signature.

Keywords: